NCT02355561View on ClinicalTrials.gov

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Healthy

Interventions

DRUG

JNJ-54861911 (Treatment A)

Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.

DRUG

JNJ-54861911 (Treatment B)

Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.

DRUG

JNJ-54861911 (Treatment C)

Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02355561 - A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants | Biotech Hunter | Biotech Hunter